文献速递炎症性肠病胃肠动力与功能性疾病

五种膳食乳化剂对炎症、肠道通透性和肠道微生物组的影响:安慰剂对照随机试验

Effect of Five Dietary Emulsifiers on Inflammation, Permeability, and the Gut Microbiome: A Placebo-controlled Randomized Trial.
PubMed 文献 · Clin Gastroenterol Hepatol · 2025-08-13

与安慰剂相比,乳化剂补充降低短链脂肪酸浓度,但未影响肠道或全身炎症及代谢终点;卡拉胶组跨细胞肠道通透性较基线增加。

要点

  • 健康成人补充羧甲基纤维素等乳化剂后短链脂肪酸浓度低于安慰剂。
  • 乳化剂补充未改变粪便钙卫蛋白、C反应蛋白等炎症或代谢标志物。
  • 卡拉胶组跨细胞肠道通透性较基线升高,提示潜在肠道屏障影响。

核心结论

  • 在健康成人中,乳化剂补充较安慰剂降低短链脂肪酸浓度,但未影响肠道或全身炎症及代谢终点。
  • 2周无乳化剂饮食后胆固醇水平下降,提示限制膳食乳化剂可能对肠道有益,需进一步研究。

研究设计与样本

  • 干预组分别补充羧甲基纤维素、聚山梨酯-80、卡拉胶、大豆卵磷脂、天然大米淀粉或安慰剂(通过布朗尼给予)。

主要发现

  • 2周无乳化剂饮食后胆固醇水平下降(P = .00006)。
  • 乳化剂补充期间α多样性保持稳定,但微生物组成受处理和访视影响。
  • 与安慰剂相比,羧甲基纤维素组所有短链脂肪酸浓度较低,其他乳化剂呈类似趋势但未全部达统计学显著。
  • 干预结束时,安慰剂与乳化剂组间粪便钙卫蛋白、C反应蛋白、血清脂多糖结合蛋白、胆固醇及其他代谢标志物无差异。
  • 卡拉胶组跨细胞肠道通透性较基线增加(P = .04)。

临床怎么用

  • 健康成人短期补充特定乳化剂未引起可检测的肠道或全身炎症,但降低短链脂肪酸并可能增加通透性。
  • 限制膳食乳化剂可能改善胆固醇,但需更多研究验证临床获益。

局限性

  • 结果来自健康人群,不能直接外推至炎症性肠病等患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Dietary emulsifier consumption might promote intestinal inflammation, eventually leading to inflammatory bowel diseases. However, human data are scarce and involve a limited number of emulsifiers. We studied the effects of an emulsifier-free diet (EFD) and specific emulsifier supplementation. METHODS: Sixty healthy participants followed an EFD for 2 weeks. Then, using a randomized placebo-controlled trial design, participants continued an EFD for 4 weeks with the addition of either carboxymethyl cellulose, polysorbate-80, carrageenan, soy lecithin, native rice starch, or no additives administered through brownies. Effects on cardiometabolic markers, gut microbiota, intestinal inflammation, and permeability were explored. RESULTS: After 2 weeks of an EFD, cholesterol levels decreased (P = .00006). Under emulsifier supplementation, alpha diversity remained stable, yet microbial composition was affected by treatment and visit. Compared with placebo, concentrations of all short chain fatty acids were lower in those consuming carboxymethyl cellulose, which was mirrored by other emulsifiers, although not all reached significance. No differences in fecal calprotectin, C-reactive protein, serum lipopolysaccharide-binding protein, cholesterol levels, or other metabolic markers were observed between placebo and emulsifiers at the end of the intervention. Serum inflammatory and cardiometabolic proteins remained unchanged. In individuals consuming carrageenan, transcellular intestinal permeability increased (P = .04) compared with baseline. CONCLUSIONS: In this double-blind placebo-controlled exploratory trial, emulsifier supplementation lowered short chain fatty acid concentration compared with placebo. Emulsifier supplementation did not impact intestinal or systemic inflammation or metabolic endpoints. Cholesterol levels decreased after 2 weeks of an EFD. These results point towards potential intestinal benefits of limiting dietary emulsifiers in the diet, requiring further investigation. CLINICALTRIALS: gov, Number: NCT06552156.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Wellens J, Vanderstappen J, Hoekx S, et al. Effect of Five Dietary Emulsifiers on Inflammation, Permeability, and the Gut Microbiome: A Placebo-controlled Randomized Trial. Clin Gastroenterol Hepatol. 2025. PMID: 40816342. doi:10.1016/j.cgh.2025.08.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。